💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, steadily growing business, reasonably priced.
Alembic is scored on the pharma / healthcare framework. It keeps a fat 40.2% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.95×). Free cash flow is worth about 2.5% of its market value.
Over the last 3 years revenue compounded at 18%/yr and profit at 16%/yr. Book value has grown 6%/yr. Return on equity is a healthy 13.0%. In the latest quarter profit grew 63% versus the prior quarter.
At 8× earnings, the stock sits at the 23rd percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price asks for only ~-4%/yr growth over a decade — undemanding expectations. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 8.11 | — | — |
| P/B | 1.06 | 4.1 | better |
| EV/EBITDA | 15.58 | 19.33 | better |
| ROE | 12.98 | — | — |
| ROCE | 6.12 | 14.41 | worse |
| ROA | 4.38 | 1.64 | better |
| Quick Ratio | 1.43 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| DLF | 40.7 | 4.1 | 10.0% |
| Macrotech Developers | 27.3 | 4.8 | 17.2% |
| The Phoenix Mills | 45.8 | 8.4 | 14.3% |
Revenue has grown every year across all 4 financial years shown. 18% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak.
Operating margin has expanded from 45% to 48% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 5% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. EPS outpaced profit growth — possible buybacks are concentrating earnings into fewer shares. 19% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 12% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (55% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate fading — recent quarters 41% below earlier ones.
Profit jumped 63% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (63% → 29%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 71.4% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.